Lilly forecasts 2025 profit largely above estimates on weight-loss drug strength
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular ...
Lilly forecasts 2025 profit growth after recent weight-loss drug worries
On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...
NBC Bay Area16d
‘Miracle' drug innovation could see a new Wegovy launch every couple of years, Larry Summers says
Miracle drug innovations — such as those that sparked the meteoric rise of Wegovy and Zepbound — could come every couple of years thanks to new technologies, former U.S. Treasury Secretary ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
MM&M1d
Lift tickets: 6 drug launches set for a hefty sales ramp
These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...
Zacks.com on MSN22h
NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up
Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...
朝日新聞社11d
Novo to launch Wegovy in Asia with February Japan roll-out
COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 next year, its first launch in Asia, the company said on Thursday, even as it struggles to keep ...
Futurism4d
Pharmacists Warn That People With Eating Disorders Are Misusing Wegovy Prescriptions
More and more people are taking weight loss injectables like Wegovy and Mounjaro — and though the drugs are gaining credibility when used properly, pharmacy experts are worried that not everyone ...